Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Atsena Therapeutics

News headline image
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present at May Scientific Conferences
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at The Macula Society’s 48th Annual Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics to Present at NewYorkBIO’s December 2022 Emerging Life Science Company Showcase
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer
From Atsena Therapeutics
Via GlobeNewswire
News headline image
Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)
From Atsena Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.